Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On February 17, 2020, West Pharmaceutical Services, Inc. (the "Company")
announced that its Board of Directors (the "Board") had elected Robert Friel as
its newest member. With the addition of Mr. Friel, the Board increased in size
to 11 directors.
Mr. Friel, age 64, recently retired as Chairman and Chief Executive Officer of
PerkinElmer, Inc., a role he served in for more than 10 years. During his
20-year career at PerkinElmer, a global business dedicated to serving the
diagnostics, life sciences, food and applied markets, Mr. Friel held roles of
increasing responsibility that included Chief Operating Officer, President of
the Life and Analytical Sciences Division and Chief Financial Officer. Prior to
joining PerkinElmer, Mr. Friel served in several finance-focused senior
management positions with AlliedSignal, Inc., now Honeywell International. Mr.
Friel sits on the Board of Directors of New York Life Insurance Company,
NuVasive, Inc. and Xylem, Inc. He has prior board experience with CareFusion,
Inc., Fairchild Semiconductor, Inc. and Millennium Pharmaceuticals, Inc.
Mr. Friel will be entitled to the customary compensation arrangements for the
Company's non-employee directors, which consists of a $90,000 annual retainer
and a restricted stock unit grant of $190,000, with the restricted stock unit
grant being prorated based on Mr. Friel's period of service in 2020. In
addition, he will be eligible to participate in the Company's Director Deferred
Compensation Plan. The Company's most recent proxy statement, filed with the
Securities and Exchange Commission on March 22, 2019, describes these
arrangements under the heading "Director Compensation".
Mr. Friel will enter into our standard form of indemnification agreement, the
form of which was included as Exhibit 10.1 to our Current Report on Form 8-K
filed on January 6, 2009.
There were no arrangements or understandings between Mr. Friel and any other
person pursuant to which he was elected as a director, and there are and have
been no transactions since the beginning of the Company's last fiscal year, or
currently proposed, between the Company and Mr. Friel.
Item 7.01 Regulation FD Disclosure.
On February 17, 2020, the Company issued a press release announcing the
appointment of Mr. Friel to the Board. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished
pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or
otherwise subject to the liabilities of that section, nor will it be
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific
referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated February 17,
2020.
104 The cover page from the Company's Current Report on Form 8-K, dated
February 17, 2020, formatted in Inline XBRL.
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
WEST PHARMACEUTICAL SERVICES, INC. 
